To understand the true Kodak digital camera history, we must separate popular myth from audited corporate documentation.

A rigorous analysis of Kodak digital camera history demonstrates that structural balance-sheet pressures, rather than technological blindness, drove the corporate outcome.

Standfirst.

Eastman Kodak filed an electronic-still-camera patent application in 1977 and secured the patent in 1978, sold digital cameras for years, and told its shareholders in 2006 that digital revenues had passed traditional revenues. In 2012 it filed for Chapter 11. Fujifilm, in the same business as the film market collapsed, is still operating. This case file goes to the primary filings of both companies and asks what the evidence can actually explain — and, just as importantly, where it runs out.

Key findings

The popular Kodak failure myth that the company simply ignored digital technology is contradicted by the primary record. US Patent 4,131,919 was filed on 20 May 1977 and granted on 26 December 1978 to Eastman Kodak Company. Kodak’s own FY2006 Form 10-K reports that digital revenues exceeded traditional revenues and that a roughly US$3 billion investment and acquisition programme was essentially complete. PCL-06, PCL-10
The two firms did not start from equivalent positions. By FY2004, Fujifilm’s Document Solutions segment accounted for 38.81% of consolidated external revenue, rising above 42% from FY2010. Kodak had separated Eastman Chemical and sold its health and pharmaceutical businesses by the end of 1994. PCL-20, PCL-25, PCL-26
That asymmetry is a revenue fact, not a proven cushion. No inspected source quantifies Fuji Xerox’s profit or cash contribution, before or after 2001. PCL-46, LIM-11
Inside one Kodak presentation, film still earned and digital did not. In Kodak’s FY2006 segment presentation for FY2004–FY2006, Film and Photofinishing produced US$854m of segment earnings on US$7,051m of FY2004 revenue, while Consumer Digital Imaging reported losses in FY2004 (−US$189m on US$2,366m) and FY2005 (−US$131m) and approximately break-even results in FY2006 (+US$1m). This is a bounded comparison between two segment lines in one presentation. It is not a company-wide cash-flow claim. PCL-12
Fujifilm did not glide through. It reported a consolidated operating loss of ¥42,112m in FY2010 and, on its own before/after restructuring figures, absorbed implied reform costs of ¥143,741m that year alone. PCL-29, PCL-30
Fujifilm also failed at something. Its Imaging Solutions segment reported operating losses in FY2011, FY2012 and FY2013 as reported at the time, while management separately retrenched the compact-camera line. The losses are a complete-segment figure; no compact-camera-only result exists in this evidence base. PCL-33, PCL-35, LIM-07
Kodak was not liquidated. It filed for Chapter 11 on 19 January 2012 and emerged as a restructured company on 3 September 2013. PCL-03, PCL-04
The strongest counterargument survives this case file. The two companies differ in currency, fiscal calendar, segment definitions, consolidation boundaries, regional exposure and legacy liabilities. Those differences are large enough that attributing the divergence to decision quality is not evidence-led. We could not establish that Fujifilm executed better. PCL-51

The case question

The question is not why Kodak missed digital photography. That framing assumes a fact the record contradicts.
In evaluating this Kodak business failure case study, the question this case file tests is narrower and harder: two firms in the same industry watched the same technology destroy the same market.One filed for bankruptcy protection; one did not. How much of that difference can documented evidence explain, and at what confidence?
A note on the title. Eastman Kodak Company exists. “What killed Kodak” refers to the collapse of its dominant film-era business model, its market position, and the shareholder value built on them — not to corporate extinction. PCL-05

Two starting positions

Kodak narrowed. Its FY1994 Form 10-K treats the Eastman Chemical separation and the sale of its health and pharmaceutical businesses as discontinued operations, reports US$7,858m of gross proceeds from the completed sales, and restates prior periods accordingly. One consequence needs stating: the FY1990–FY1994 figures in that filing are restated continuing-operations presentations, not untouched contemporaneous totals. PCL-20 (A-29)
Fujifilm broadened. Fuji Photo Film was established on 20 January 1934. Its Fuji Xerox joint venture dates from 1962, with Fujifilm holding 50%. In 2001 Fujifilm acquired a further 25% from Xerox Corporation, reaching 75%.
The accounting detail matters more than the headline. Fuji Xerox’s balance sheet was consolidated at 31 March 2001, while FY2001 operations remained equity-accounted at the pre-acquisition 50% basis. FY2001 to FY2002 is therefore a genuine consolidation boundary, not a growth trend. PCL-25 (A-08, A-23, A-35)
The resulting scale, calculated by dividing Fujifilm’s reported Document Solutions external revenue by its reported consolidated revenue:
Fiscal year (ended 31 March) Document Solutions external revenue (¥m) Consolidated revenue (¥m) Share
FY2004 996,039 2,566,725 38.81%
FY2008 1,191,628 2,846,828 41.86%
FY2010 935,360 2,181,693 42.87%
FY2011 973,889 2,217,084 43.93%
FY2012 (original presentation) 984,829 2,195,293 44.86%
Source: A-27 printed p. 3 / PDF p. 7; A-38 segment table; A-39 printed p. 49 / PDF p. 50. Calculations CALC-2B-07–CALC-2B-11.
The necessary caution. This is external revenue divided by consolidated revenue. It is not profit, not cash generated for shareholders, not return on capital, and not a measure of resilience. Fuji Xerox’s contribution net of non-controlling interests and intercompany effects is unresolved, and its pre-2001 contribution is entirely unquantified. Anyone presenting this share as proof of a financial cushion has gone beyond the evidence. PCL-46, LIM-11

Deconstructing Kodak Digital Camera History

Re-evaluating Kodak digital camera history requires separating late-stage corporate restructuring from early-stage research and development achievements.

The Steve Sasson Digital Camera Patent

The Steve Sasson digital camera patent (US Patent 4,131,919, “Electronic still camera”) names G. A. Lloyd and S. J. Sasson as inventors and Eastman Kodak Company as assignee. Filed 20 May 1977; granted 26 December 1978. The full bibliographic record, description and all eight claims were inspected — through a Google Patents reproduction rather than a USPTO original, which is recorded as a limitation. PCL-06 (A-01)

The prototype.

The IEEE/ETHW milestone record, dedicated in 2022, credits a Kodak team led by Steven Sasson with building a working handheld digital camera prototype in December 1975. This is an institutional retrospective account and is attributed as such. No claim is made in this case file about how anyone inside Kodak responded to it. Internal-reaction stories about that prototype rest on retrospective participant accounts that we did not inspect, and they are excluded from this package entirely. PCL-07 (A-13), LIM-15

The transformation programme.

Kodak’s FY2003, FY2005 and FY2006 filings document digital cameras, retail kiosks, online photo services, image sensors and acquisitions in commercial graphics. In FY2006 Kodak reports that digital revenues had exceeded traditional revenues and that the roughly US$3bn investment and acquisition plan launched under its 2003 strategy was essentially complete. The same filings warn about rapid price declines in digital products and competition from consumer-electronics companies. PCL-09, PCL-10, PCL-11 (A-16, A-17, A-31)
This is the evidential core of the myth correction. Kodak’s own disclosures, made while the outcome was still open, describe an institution that had diagnosed the substitution and was spending against it at scale.

The shape of the collapse

Key inflection points throughout Kodak digital camera history reveal how legacy operational commitments eroded margins even as consumer digital adoption accelerated.

Segment economics.

Under Kodak’s FY2006 presentation (A-31, pp. 143–144):
FY Consumer Digital Imaging revenue (US$m) CDG segment result (US$m) Film & Photofinishing revenue (US$m) FPS segment result (US$m)
2004 2,366 −189 7,051 854
2005 3,215 −131 5,325 540
2006 2,920 +1 4,156 358
Under the later FY2007 presentation, after the Health Group disposal (A-32, p. 105, Note 24), the same calendar years carry different figures:
FY Consumer Digital Imaging revenue (US$m) CDG segment result (US$m) Film Products revenue (US$m) Film Products result (US$m)
2005 5,646 −374 2,841 573
2006 4,711 −240 2,312 368
2007 4,631 −92 1,968 369
These are not contradictory and neither is an error. They are two legitimate issuer presentations under different discontinued-operations and segment boundaries. We preserve both and never average or splice them. PCL-12, PCL-13, LIM-03
Under the reporting structure effective 1 January 2008 (A-42, Note 23 quantitative segment table, printed p. 99 / viewer p. 101), FY2008 segment sales were US$3,088m (Consumer Digital Imaging), US$2,987m (Film, Photofinishing and Entertainment), US$3,334m (Graphic Communications) and US$7m (All Other), with filing-defined segment measures of −US$177m, +US$196m, +US$31m and −US$17m. Consolidated net sales were US$9,416m; the statement-level loss before interest, other income and taxes was −US$821m. PCL-14

Top line.

US$15,968m (FY1996) → US$13,994m (FY2000) → US$10,301m (FY2007) → US$9,416m (FY2008) → US$6,248m (FY2009) → US$4,438m (FY2010) → US$3,585m (FY2011). This is not one continuous scope. Boundary breaks occur at the 1994 discontinued-operations treatment, the 2006 inventory-costing change, the 2007 Health Group disposal, the 2008 reporting restructure, and the later restatement of 2011 for the Personalized Imaging and Document Imaging discontinued classification — a restatement that was not applied to 2009 and 2010 in the same table. PCL-15, LIM-03

Restructuring.

Statement-line charges of US$659m (FY2001), US$484m (FY2003), US$695m (FY2004), US$690m (FY2005), US$471m (FY2006), US$543m (FY2007) and US$140m (FY2008). Kodak’s segment-reconciliation restructuring amounts differ in scope from the statement line and are not substituted for it. PCL-17

Legacy obligations.

Kodak reported US pension projected benefit obligations of US$6,204m and non-US obligations of US$3,784m at FY2005; US$5,557m and US$4,067m at FY2006; and other-postretirement net benefit obligations of US$3,061m and US$3,009m. Its FY2008 balance sheet reports a combined pension and other-postretirement liability of US$2,382m — a different definition that must not be read as a decline in the same measure. PCL-19, LIM-10

The pension settlement.

Kodak’s filings state that the KPP Global Settlement resolved approximately US$2.8 billion of claims by its UK pension trustee, which Kodak identified as the largest creditor in the Chapter 11 proceedings. On the 3 September 2013 effective date, the Personalized Imaging and Document Imaging businesses transferred for a total purchase price excluding assumed liabilities of US$650m: US$525m in cash (US$325m sourced from UK Pension Plan assets, US$200m from a Kodak Limited payment) plus a US$125m note subsequently cancelled by assignment and set-off. PCL-24 (A-15 Item 2.01, inspected in full; A-04 Item 8.01)

The patent sale.

— a figure worth getting right. The Patent Sale Agreement sets a cash purchase-price base of US$527,000,000 less licence fees plus an expense adjustment, within a defined aggregate-transaction-value corridor. Kodak separately reported receiving approximately US$530m in February 2013 related to the sale and licensing of certain IP assets. The widely circulated “approximately US$525m” figure was not primary-verified and is excluded from this case file. It must not be confused with the unrelated US$525m cash component of the pension settlement. PCL-23, CONF-2B-05
The market. By Fujifilm’s own retrospective account, global colour-film demand peaked in 2000 and had fallen to below one-tenth of that peak by around 2010. Falling from an index of 100 to below 10 over ten years implies an equivalent constant annual decline steeper than −20.57%. For comparison, a constant −10% annual decline would leave 34.87 index points after ten years — inconsistent with the same source’s own endpoint. No year-by-year series was obtained; 2001–2009 are genuine gaps. PCL-39, CALC-2B-12, CALC-2B-13

What Fujifilm’s diversification actually was

Not one mechanism. Four, running simultaneously:
Class Examples Evidence What it does not establish
Inherited Fuji Xerox relationship; medical imaging; photographic and graphic materials A-08, A-23, A-27, A-35 Pre-2001 Fuji Xerox net contribution; comparable profits
Organic redeployment Specialty and display materials; medical imaging and IT extensions A-27, A-37, A-38, A-39 What fraction of later profit came from transferred film chemistry
Acquired Toyama Chemical (66%); SonoSite A-27 Note 18; A-43 Gross tender economics; Taisho’s completed holding; acquisition-adjusted returns
Consolidation effect 2001 Fuji Xerox stake increase A-08, A-35, A-27, A-39 That the resulting revenue was organic redeployment

Toyama, precisely.

Fujifilm’s annual report states the tender offer ran from 19 February to 18 March 2008 and that Toyama became a consolidated subsidiary. Its audited Note 18 records the completed acquisition of 66% of Toyama’s common stock in March 2008 at a net acquisition cost of ¥97,858m, including ¥116,112m of goodwill and other intangibles. The report describes the ultimate 66/34 split with Taisho Pharmaceutical as the scheduled end state, not as a completed division of shares. The ~¥155bn aggregate and ~¥880-per-share figures rest on secondary indexed reporting only; the original tender press release was never located. Those figures are excluded as verified facts. PCL-31, LIM-12, EX-2C-10

VISION75.

Fujifilm’s own annual report states the plan was inaugurated in 2004, that approximately ¥200 billion was spent on structural reform of Imaging Solutions over the two years from FY2006, that it was updated in 2007 and 2008, and that its FY2010 targets were ¥3,050 billion of revenue and over ¥250 billion of operating income. This is unaudited issuer narrative, outside the scope of the independent auditor’s opinion in that report. PCL-28

Cosmetics.

ASTALIFT launched in 2007 by Fujifilm’s own account. Nothing in the evidence base establishes a sufficient or dominant contribution to survival, and the claim that cosmetics saved Fujifilm is excluded. PCL-38, EX-2C-04

The healthcare contrast.

Kodak acquired Imation’s worldwide medical-imaging business on 30 November 1998 (Kodak stated it had about US$500m of annual revenue). Kodak completed the sale of its Health Group on 30 April 2007. Fujifilm consolidated Toyama in March 2008. This is presented as a capital-allocation contrast under uncertainty, not as a verdict on either decision. PCL-21, PCL-22, PCL-31

What survival cost Fujifilm

Fiscal year (ended 31 March) Imaging Solutions external revenue (¥m) Consolidated operating income after restructuring (¥m) Before restructuring (¥m) Implied reform amount (¥m)
FY2005 742,993 164,442 — —
FY2006 689,458 70,436 156,479 86,043
FY2007 605,383 113,062 207,143 94,081
FY2008 547,066 207,342 207,342 0
FY2009 410,399 37,286 70,769 33,483
FY2010 345,489 −42,112 101,629 143,741
FY2011 325,804 136,356 168,071 31,715
FY2012 (original) 322,706 112,948 — —
Sources: A-27 printed p. 3 / PDF p. 7 and Ten-Year Summary printed p. 48 / PDF p. 52; A-37 and A-38 Financial Highlights; A-39 printed p. 49 / PDF p. 50. Implied reform amounts are researcher calculations CALC-2B-01–CALC-2B-06 (before-restructuring operating income minus after-restructuring operating income). PCL-27, PCL-29, PCL-30
FY2012 has two presentations. The original reports consolidated revenue of ¥2,195,293m and operating income of ¥112,948m. Fujifilm’s official notice of 31 July 2017 amended these to ¥2,180,996m and ¥109,260m — reductions of ¥14,297m and ¥3,688m. The notice states that inappropriate accounting at overseas Fuji Xerox subsidiaries, together with other reconfirmation and correction items, required the amendments. Both presentations are preserved separately. PCL-37 (A-40)
Why no side-by-side comparison appears anywhere in this case file. Kodak reports in nominal US dollars on a December year-end under segment definitions that changed at least four times. Fujifilm reports in nominal yen on a March year-end under its own definitions, with a major consolidation boundary in 2001 and a retrospective amendment in 2017. No currency conversion and no inflation adjustment were performed. Cross-company revenue, debt, cash-flow, restructuring and acquisition amounts are therefore not compared, and no cross-company operating-margin ranking is made. LIM-01, LIM-02, EX-2C-11

The failure on the other side

Studying a survivor without looking for its failures produces survivorship bias. The control:
Lane A — as reported at the time (A-43, PDF p. 100). Imaging Solutions operating income/(loss): FY2011 −¥12,693m; FY2012 −¥3,981m; FY2013 −¥2,212m.
Lane B — the later corrected presentation (A-46, JPX PDF p. 18). FY2014 Imaging Solutions operating income +¥3,581m, with a comparative FY2013 operating loss of −¥776m.
These two lanes are kept separate and are never combined. The corrected FY2012 disclosure object was identified by official route but its body could not be opened in the available retrieval layer, and no qualifying complete reproduction was found. The exact amended FY2011 and FY2012 segment values are therefore not established, and no candidate figures are used anywhere in this package. PCL-33, PCL-34, LIM-06
Scope, stated plainly. Imaging Solutions covers colour film, digital cameras, optical devices, photofinishing equipment, photo paper, chemicals and services. No compact-camera-only profit or loss exists in this evidence base. Attributing these segment figures to compact cameras alone would misstate the record. LIM-07
The retrenchment. Fujifilm’s FY2013 management reporting records falling compact-camera demand, a plan to roughly halve the number of compact models, and a targeted 20–30% reduction in development and fixed costs. Reuters reporting from 31 December 2013 independently describes camera-business losses, smartphone erosion of the compact category and product-line retreat across Japanese camera makers — the only genuinely independent corroboration in this part of the case. PCL-35, PCL-36
The conclusion this supports is narrow and important: the survivor was not clairvoyant. Whether diversification supplied the capacity to absorb those errors remains plausible, not proven — portfolio resilience sits at Level 4 throughout this case file, and asserting the mechanism here would contradict that grading. This section does not support any claim that Fujifilm’s overall strategy was no better than Kodak’s, and it does not increase the causal weight of Fujifilm’s failures in the verdict.

The strongest counterargument

Stated at full strength, and not defeated here.
The comparison may be too weak to support conclusions about decisions. Six material non-equivalences are documented: currency; fiscal year end; segment definitions (both firms changed them repeatedly); consolidation boundaries; regional exposure; and starting portfolios. Kodak’s legacy obligations are documented in its own filings, but no directly comparable Fujifilm liability series exists, so no comparative legacy-liability non-equivalence is established and none is claimed here. If those six differ this much, the divergence in outcomes may be reporting inheritance and structure rather than judgment. LIM-10, UR-2C-02
Kodak’s decisions were defensible at the time they were made. Building a digital camera business as film declined; investing roughly US$3bn in a digital transition; selling a health business during a cash squeeze. Judged against contemporaneous information rather than the ending, these are the actions of an institution acting on a correct diagnosis.
Execution superiority could not be established. Isolating execution quality requires matched initiatives with matched objectives, matched resources, comparable accounting scope and comparable market conditions. That matched set does not exist in this evidence base. Apparent execution differences cannot be separated from structural ones. PCL-51, EX-2C-14
The home-market question is unresolved. The United States requested WTO consultations over Japanese film and paper measures on 13 June 1996; a panel was established on 16 October 1996; its report was circulated on 31 March 1998 and adopted on 22 April 1998. The Panel concluded that the United States had not demonstrated its claims under GATT Articles XXIII:1(b), III:4 and X:1. It separately found that the US had not shown the cited distribution measures caused Japan’s single-brand distribution structure, since that structure appears to have predated the measures; that several measures were not shown to remain operative; that any legitimate expectations from unanticipated measures would apply only to black-and-white film, agreed by the parties to be roughly 3% of the market; and it rejected the combined-effects theory for want of additional evidence.
What that does and does not mean. “Not demonstrated” is a finding about the evidentiary record before that panel. It is not an affirmative finding that the alleged effects never existed, and it is not a measurement of anyone’s margins. Most of the Panel’s reasoning remains unread in this evidence base. The economic timing question stays open. PCL-42, PCL-43, PCL-44, LIM-14

The qualified verdict

Ultimately, Kodak digital camera history provides a definitive case study on financial flexibility during severe market transitions.

Established as documented fact. Kodak developed and commercialised substantial digital products and services for decades before its bankruptcy filing. The two firms did not enter the disruption from equivalent portfolio positions. Kodak carried large, contemporaneously documented legacy liabilities of its own — a record of Kodak’s obligations, from which nothing comparative follows, because no comparable normalized Fujifilm series exists. Film’s scale-down economics imposed severe restructuring burdens on both firms. Fujifilm’s Imaging Solutions segment reported multi-year operating losses, while management separately retrenched the compact-camera line. PCL-45, LIM-07, LIM-10
Supported as contributing mechanisms — not as the cause. Fujifilm’s redeployment of pre-existing capabilities into adjacent businesses, alongside inherited, acquired and consolidated businesses. Film-manufacturing scale-down economics at both firms. External shocks — the financial crisis, then smartphone substitution — as amplifiers of differences that already existed. PCL-47, PCL-50, PCL-52
Plausible but unproven. That portfolio asymmetry actually increased Fujifilm’s resilience. That Kodak’s documented legacy liabilities constrained it relative to Fujifilm — we hold Kodak’s figures and no comparable Fujifilm series. That execution quality differed. That home-market timing favoured Fujifilm. Each is believable. None is demonstrated by the current record. PCL-46, PCL-48, PCL-49, PCL-51, LIM-10
Excluded. That Kodak ignored digital. That Kodak invented digital and buried it. That Fujifilm was simply smarter. That cosmetics saved Fujifilm. That any single decision was decisive. That bankruptcy was inevitable. PCL-53
The bounded conclusion. The divergence is best represented as a combined-mechanism outcome with different evidence levels by mechanism — not as a single causal story, and not as a uniformly supported model. The evidence supports the claim that these firms did not start from the same place. It does not support ranking the causes, assigning percentages to them, or converting a difference in outcomes into a difference in intelligence, courage or foresight. PCL-54

Chronology

Date Entity Event Class Source / locator
20 Jan 1934 Fujifilm Fuji Photo Film Co., Ltd. established Attributed (issuer history) A-08
Dec 1975 Kodak Team led by Steven Sasson builds a handheld digital camera prototype Attributed (IEEE/ETHW) A-13
20 May 1977 / 26 Dec 1978 Kodak US Patent 4,131,919 filed / granted Documented fact A-01
1962 Fujifilm Fuji Xerox joint venture formed (50% Fujifilm) Attributed (issuer history) A-08, A-23
1993–1994 Kodak Eastman Chemical separated; health and pharma sales completed; US$7,858m gross proceeds Documented fact A-29
30 Nov 1998 Kodak Imation worldwide medical-imaging business acquired Documented fact A-18
13 Jun 1996 – 22 Apr 1998 — WTO DS44: consultations requested → panel established → report circulated → adopted Documented fact A-09, A-26
30/31 Mar 2001 Fujifilm Additional 25% of Fuji Xerox acquired from Xerox Corporation; balance sheet consolidated; FY2001 operations still equity-method at 50% Documented fact (accounting boundary) A-35, A-08
2004 Fujifilm VISION75 inaugurated Attributed (issuer narrative) A-27
2006 Fujifilm Holding-company transition to FUJIFILM Holdings Documented fact A-22, A-23
FY2006 Kodak Reports digital revenues exceeded traditional revenues; ~US$3bn programme essentially complete Documented fact (issuer report) A-31
30 Apr 2007 Kodak Health Group sale completed; moved to discontinued operations Documented fact A-32
19 Feb – 18 Mar 2008 Fujifilm Toyama Chemical tender-offer period Documented fact (issuer report) A-27 p. 11
Mar 2008 Fujifilm 66% of Toyama acquired; net acquisition cost ¥97,858m; consolidated Documented fact (audited note) A-27 Note 18
1 Jan 2008 Kodak New reporting structure effective Documented fact A-32, A-42
19 Jan 2012 Kodak Chapter 11 filed, SDNY Case No. 12-10202 (ALG) Documented fact A-02
Feb 2013 Kodak ~US$530m reported received for sale/licensing of certain IP assets Documented fact A-02 p. 24; A-33 §3.1
29 Apr 2013 Kodak KPP Global Settlement announced, resolving ~US$2.8bn of claims Documented fact A-04 Item 8.01
3 Sep 2013 Kodak Emerged from Chapter 11; fresh-start accounting from 1 Sep 2013 Documented fact A-15, A-02
FY2011–FY2013 Fujifilm Imaging Solutions operating losses as reported at the time Documented fact (then-reported lane) A-43 PDF p. 100
31 Dec 2013 — Reuters reports camera-business losses and compact retreat across Japanese makers Documented fact C-12s
31 Jul 2017 Fujifilm Official notice amending prior-year earnings releases Documented fact A-40

What this case file could not establish

LIM-01 No currency conversion or inflation adjustment. · LIM-02 No cross-company segment comparability. · LIM-03 Kodak’s series contains five accounting boundary breaks. · LIM-04 Fujifilm FY1999–FY2004 has two unreconciled issuer presentations. · LIM-05 FY2012 exists in original and amended form. · LIM-06 Amended FY2011/FY2012 Imaging Solutions values unresolved. · LIM-07 No compact-camera-only P&L. · LIM-08 No year-by-year film-demand series. · LIM-09 No usable digital-camera market-share figure. · LIM-10 No comparable Fujifilm pension/OPEB series. · LIM-11 Fuji Xerox pre-2001 and net contribution unquantified. · LIM-12 Toyama gross tender terms and Taisho’s completed holding unverified. · LIM-13 Most academic sources not opened in full. · LIM-14 Most of the WTO panel’s reasoning unread. · LIM-15 The 1981 internal Kodak study reaches us only through a chain running from a participant’s own 2011 memoir — which we did not inspect — to a 2012 commentary by an author who discloses that the participant is his colleague. No copy of the study has been located. Excluded entirely. · LIM-16 The originals behind two widely circulated executive quotations could not be opened, and for one of them it is unresolved whether the words are the executive’s or the reporter’s characterisation. Both are excluded, and no characterisation of Kodak’s institutional attitude is attributed to any named executive anywhere in this case file. · LIM-17 A 2006 Fujifilm identity question is attributed in its publisher-authoritative source to an unnamed chief executive. Excluded; no individual is named. The 2006 identity-redefinition entry in the chronology rests on Fujifilm’s own Tier A records and does not depend on it. · LIM-18 The canonical text of one Tier B article could not be opened at the passage carrying an attributed executive explanation; the publisher’s free preview ends before it. That explanation is not used.

Methodology and source transparency

Inspection honesty. Every source in the notes below carries an inspection status. A search snippet, an index entry, an abstract, a metadata record or a retrieval route is not direct inspection, and is never presented as evidence of content.
Reproductions are labelled. Several sources were inspected through non-canonical hosts rather than the issuer’s or regulator’s own site. A reproduction confirms what a document says; it is the same underlying work seen through an intermediary, and it is never described as the original.
Same-issuer records are not independent corroboration. Fujifilm’s history page, company profile page and annual reports are all Fujifilm. They can be mutually consistent without being mutually confirming. The same applies to Kodak’s multiple filings.
Presentations are never merged. Where an issuer has reported the same period under two boundaries, both are preserved and labelled. Nothing is averaged, spliced or silently substituted.
Calculations are disclosed. Every researcher calculation states its numerator, denominator, formula and rounding, and is identified by a calculation ID.
No quotations. This case file contains no direct quotation from any source. Everything is paraphrased and attributed. Four widely circulated quotation claims attached to this story were traced through the available provenance record and are excluded or held, precisely because canonical or original verification could not be completed: for two of them the original record could not be opened at all, for one the publisher-authoritative source names no speaker, and for one the canonical text lies behind a publisher’s meter whose accessible scope ends before the passage. None of the four was verified against its original, and no claim that any of them was is made anywhere in this case file. We would rather tell you that than reprint wording we could not verify.
Confidence is graded, not asserted. Causal propositions carry an explicit level: established sequence, supported association, supported contributing mechanism, plausible but unproven, or excluded.
Corrections. If any figure, locator or characterisation here is wrong, we will correct it in place, date the correction and describe what changed. Corrections notice: verdictofideas.com/corrections.
Editorial independence. This case file was produced with no sponsor, no affiliate relationship, no paid placement and no commercial relationship with any company named. Neither Eastman Kodak Company nor FUJIFILM Holdings Corporation has reviewed, approved or contributed to it.
AI use. Drafting and evidence-organisation work was AI-assisted under human direction. Every claim is mapped to an accepted inspected-source record in the controlled evidence chain, and every such record carries its own explicit inspection status — including the records that could not be opened. The case file is subject to independent audit and to human review and approval before publication.